Devices Radiology Oncology Regulatory

 News Release - March 25, 2019

Elekta Unity MR-linac Receives Medical Device License From Health Canada

New system for the delivery of radiotherapy using Magnetic Resonance Imaging to enhance personalized cancer treatment in Canada

TORONTO, March 25, 2019 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST) today announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received a Medical Device License from Health Canada, clearing the technology for commercial sales in Canada.

"We are pleased to have achieved this important milestone toward making Elekta Unity available in Canada and expect that this important new treatment option will become available to patients later this year, subsequent to receiving a service license from the Canadian Nuclear Safety Commission," said Richard Hausmann, Elekta President and CEO. "Researchers and clinicians from the Odette Cancer Centre at Sunnybrook Health Sciences Centre and Princess Margaret Cancer Centre have played critical roles in developing and evaluating this transformative technology, and we look forward to the day when their patients and other Canadian cancer patients will have access to this transformative approach to radiation therapy."

Elekta Unity combines a high-field 1.5T Philips MRI scanner with a best-in-class linear accelerator and breakthrough real-time dose replanning software that are fully integrated to enable online adaptive radiotherapy and real-time target monitoring. It provides the ability to reshape the dose based on daily changes in shape, size and position of the tumor and surrounding healthy anatomy and then enables accurate dose delivery with real-time visualization of the tumor.

To learn more, visit elekta.com/Unity.

Elekta Unity is CE marked and 510(k) cleared. Not commercially available in all markets.

About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Source: Elekta

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.